Ibio Stock Price, News & Analysis

iBio (NASDAQ: IBIO) will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 10–12, 2025. CEO and Chief Scientific Officer Martin Brenner, DVM, Ph.D. will appear in a fireside chat on November 10, 2025 at 8:30 a.m. ET to discuss iBio's progress toward becoming a clinical-stage biotechnology company and updates on its next-generation obesity antibody pipeline. CFO Felipe Duran will be available for one-on-one meetings during the conference. A livestream will be available, and a replay link will be posted on the Investor section of iBio's website.

iBio (NASDAQ:IBIO) will present new preclinical data on its Activin E antibody, IBIO-610, at two scientific conferences in November 2025. Cory Schwartz, Ph.D. will deliver an oral presentation at ObesityWeek on Nov 4, 2025 and a poster on Nov 5. Martin Brenner, DVM, Ph.D. will present at PEGS Europe on Nov 12, 2025. The company highlights non-human primate data suggesting fat-selective weight loss, potential support for long-term weight maintenance, and possible synergy with GLP-1 therapies.

iBio (NASDAQ:IBIO) reported its fiscal year 2025 results and corporate updates, highlighting significant progress in its cardiometabolic and obesity pipeline. The company's lead candidates include IBIO-610, an activin E-targeting antibody showing 26% fat mass reduction without lean mass loss, and IBIO-600, a long-acting anti-myostatin antibody demonstrating extended half-life and dose-dependent muscle growth.

Financial highlights include revenue of $0.4M (up $0.2M YoY), R&D expenses of $8.3M (up $3.1M), and G&A expenses of $10.7M (down $1.0M). The company strengthened its position through a $50M public offering with potential for additional $50M from warrant exercises. iBio successfully transferred to Nasdaq trading and expanded its leadership team with industry veterans.

iBio (Nasdaq: IBIO) has successfully closed its previously announced public offering, raising initial gross proceeds of $50 million. The offering included pre-funded warrants to purchase 71,540,000 shares and accompanying Series G and H warrants. If all warrants are exercised, iBio could receive an additional $50 million in gross proceeds.

The offering was led by Balyasny Asset Management with participation from several prominent investors. The proceeds will be used to advance iBio's preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, through key development milestones. Leerink Partners served as the lead bookrunner, with LifeSci Capital and Oppenheimer & Co. as bookrunning managers.

The Series G warrants are linked to a Trial Initiation Milestone and will expire either 30 trading days after the milestone announcement or five years from issuance, while Series H warrants have a four-year term.

iBio (Nasdaq: IBIO) has announced the pricing of a $50 million public offering of pre-funded warrants and accompanying Series G warrants. The offering includes 71,540,000 pre-funded warrants to purchase common stock and Series G warrants to purchase 35,770,000 shares, along with Series H warrants.

The combined offering price is set at $0.699 per unit, with Series G and H warrants having an exercise price of $0.70 per share. If all warrants are exercised, iBio could receive additional gross proceeds of approximately $50 million. The company plans to use the proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and fund working capital requirements.

[ "Potential total gross proceeds of up to $100 million if all warrants are exercised", "Funds will advance key preclinical cardiometabolic programs IBIO-610 and IBIO-600", "Multiple tier-1 investment banks involved in the offering including Leerink Partners as lead bookrunner" ]

iBio (Nasdaq: IBIO), an AI-driven precision antibody therapies company, has announced a proposed underwritten public offering. The offering includes pre-funded warrants to purchase common stock and accompanying Series G and Series H warrants.

The company plans to use the proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 (myostatin and activin A bispecific) and IBIO-600 programs, as well as other preclinical pipeline assets. Leerink Partners is leading the offering as the lead bookrunning manager, with LifeSci Capital and Oppenheimer & Co. serving as additional bookrunning managers.

iBio (NASDAQ:IBIO) has announced promising preclinical results for its novel amylin receptor agonist antibody in obesity treatment. The engineered antibody demonstrated a significant 60% reduction in acute food intake in mouse models, comparable to the 67% reduction achieved by a clinically advanced DACRA peptide.

This marks the third target from iBio's partnership with AstralBio, leveraging their AI-enabled antibody discovery platform to develop selective amylin receptor targeting treatments. The approach shows potential for both monotherapy and combination therapy with GLP-1 receptor agonists, with current amylin analogs achieving up to 22.7% weight loss in combination with semaglutide and 11.8% as monotherapy in clinical development.

iBio (NASDAQ:IBIO) has announced a conference call scheduled for June 24, 2025, at 8:30 a.m. ET to discuss its obesity and cardiometabolic disease pipeline. CEO and CSO Martin Brenner will present updates on the company's next-generation antibody medicines, including IBIO-600, their long-acting Myostatin treatment, and new preclinical data on Activin E.

The presentation will also reveal a third target in their AstralBio Collaboration. The company aims to develop targeted, longer-lasting therapies with improved tolerability and sustainable efficacy. Investors can access the webcast through iBio's website, with a replay available for approximately 60 days.

iBio has initiated a non-human primate (NHP) study for IBIO-610, its first-in-class Activin E antibody candidate, following promising preclinical results. The study will evaluate pharmacokinetics and efficacy in obese, elderly NHPs, with initial data expected in early Q4. Preclinical data showed IBIO-610 achieved 8.9% body weight loss alone and demonstrated significant fat reduction capabilities: 26% overall fat reduction and 31% subcutaneous fat reduction. When combined with GLP-1 therapy, these numbers increased to 77% and 74% respectively. Notably, IBIO-610 prevented weight regain after GLP-1 treatment discontinuation in diet-induced obese mice. These findings will be presented at the American Diabetes Association's 85th Scientific Sessions on June 23rd in Chicago.